Healthcare / BiotechnologyNasdaqGS
$12.97
-0.15 (-1.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-162.7M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
33.0%
↑Gross Margin
N/A
•Debt/Equity
-0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
+55.9%
FCF CAGR
—
FCF margin
-640.1%
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $31.9M · net income $-203.2M · FCF $-204.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $31.9M | $31.9M | $20.5M |
| Net Income | $-203.2M | $-203.2M | $-173.8M |
| EBITDA | $-208.5M | $-208.5M | $-163.7M |
| EPS | -2.18 | -2.18 | -2.09 |
| Operating Margin | -737.0% | -737.0% | -962.6% |
| Net Margin | -637.0% | -637.0% | -849.4% |
| Balance Sheet | |||
| Debt/Equity | -0.11 | -0.11 | -0.18 |
| Current Ratio | 9.17 | 9.17 | — |
| Cash Flow | |||
| Free Cash Flow | $-204.1M | $-204.1M | $-121.2M |
| Returns | |||
| ROE | 33.0% | 33.0% | 40.0% |
| Growth & Yield | |||
| Revenue Growth | 55.9% | 55.9% | — |
| EPS Growth | -4.3% | -4.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.09 → -2.18
Residual
+2.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.